GB0608928D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB0608928D0
GB0608928D0 GBGB0608928.8A GB0608928A GB0608928D0 GB 0608928 D0 GB0608928 D0 GB 0608928D0 GB 0608928 A GB0608928 A GB 0608928A GB 0608928 D0 GB0608928 D0 GB 0608928D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0608928.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB0608928.8A priority Critical patent/GB0608928D0/en
Publication of GB0608928D0 publication Critical patent/GB0608928D0/en
Priority to US12/299,833 priority patent/US8232390B2/en
Priority to AU2007246850A priority patent/AU2007246850B2/en
Priority to CNA2007800166679A priority patent/CN101437826A/zh
Priority to CA002651226A priority patent/CA2651226A1/en
Priority to PCT/GB2007/050239 priority patent/WO2007129119A1/en
Priority to JP2009508506A priority patent/JP5276582B2/ja
Priority to EP07733660A priority patent/EP2027125A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0608928.8A 2006-05-08 2006-05-08 Therapeutic agents Ceased GB0608928D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0608928.8A GB0608928D0 (en) 2006-05-08 2006-05-08 Therapeutic agents
US12/299,833 US8232390B2 (en) 2006-05-08 2007-05-04 Pentacyclic indole derivatives as antiviral agents
AU2007246850A AU2007246850B2 (en) 2006-05-08 2007-05-04 Pentacyclic indole derivatives as antiviral agents
CNA2007800166679A CN101437826A (zh) 2006-05-08 2007-05-04 作为抗病毒剂的五环吲哚衍生物
CA002651226A CA2651226A1 (en) 2006-05-08 2007-05-04 Pentacyclic indole derivatives as antiviral agents
PCT/GB2007/050239 WO2007129119A1 (en) 2006-05-08 2007-05-04 Pentacyclic indole derivatives as antiviral agents
JP2009508506A JP5276582B2 (ja) 2006-05-08 2007-05-04 抗ウイルス剤としての五環インドール誘導体
EP07733660A EP2027125A1 (en) 2006-05-08 2007-05-04 Pentacyclic indole derivatives as antiviral agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0608928.8A GB0608928D0 (en) 2006-05-08 2006-05-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB0608928D0 true GB0608928D0 (en) 2006-06-14

Family

ID=36604009

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0608928.8A Ceased GB0608928D0 (en) 2006-05-08 2006-05-08 Therapeutic agents

Country Status (8)

Country Link
US (1) US8232390B2 (enExample)
EP (1) EP2027125A1 (enExample)
JP (1) JP5276582B2 (enExample)
CN (1) CN101437826A (enExample)
AU (1) AU2007246850B2 (enExample)
CA (1) CA2651226A1 (enExample)
GB (1) GB0608928D0 (enExample)
WO (1) WO2007129119A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
US8143243B2 (en) 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
BRPI0821342A2 (pt) 2007-12-19 2019-09-24 Boehringer Ingelheim Int inibidores da polimerase viral
JP2011507906A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー フラビウイルス感染の治療に用いるための縮合5環式誘導体
KR20100124848A (ko) * 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 hcv ns5b 억제제
WO2009120733A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
CN101977914A (zh) 2008-03-27 2011-02-16 百时美施贵宝公司 用于治疗丙型肝炎的化合物
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンhcvns5b阻害剤
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
JP5536229B2 (ja) * 2009-12-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hcv併用療法
PL2767578T3 (pl) 2013-02-19 2016-09-30 Sposób i aparat do przygotowywania oleju cylindrowego

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
ES2156725B1 (es) 1999-05-07 2002-03-01 Consejo Superior Investigacion Derivados de dioxidos n,n- y n,x-disustituidos de 1,2,6-tiadiazina fusionadas y procedimiento de obtencion.
JP4299540B2 (ja) 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー C型肝炎ウイルスレプリコンおよびレプリコン増強細胞
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
EP1719773B1 (en) 2004-02-24 2009-04-15 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005298412B2 (en) * 2004-10-26 2011-06-09 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7795247B2 (en) * 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) * 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
WO2007129119A1 (en) 2007-11-15
US8232390B2 (en) 2012-07-31
US20100009959A1 (en) 2010-01-14
AU2007246850B2 (en) 2012-07-05
CN101437826A (zh) 2009-05-20
JP5276582B2 (ja) 2013-08-28
JP2009536189A (ja) 2009-10-08
CA2651226A1 (en) 2007-11-15
AU2007246850A1 (en) 2007-11-15
EP2027125A1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL196559A0 (en) Combination therapy
IL201235A0 (en) Therapeutic agents
GB0506147D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
GB0723747D0 (en) Therapeutic agents
EP2054061A4 (en) COMBINATION THERAPY
GB0616214D0 (en) Therapeutic Agents
GB0724340D0 (en) Novel Therapeutic Agents
GB0519797D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
ZA200902203B (en) Combination therapy
GB0518819D0 (en) Therapeutic agents
GB0611152D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
GB0723748D0 (en) Therapeutic agents
GB0622195D0 (en) Therapeutic agents
GB0601068D0 (en) Therapeutic Agents
GB0602153D0 (en) Therapeutic agents
GB0620062D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)